Although an association between the tumour aggressiveness and the overexpression of EZH2 has been well documented for breast cancer (Kleer et al, 2003; Raaphorst et al, 2003) and prostate cancer (Sellers and Loda, 2002; Varambally et al, 2002; Rhodes et al, 2003; Foster et al, 2004), little is known about the expression status of EZH2 in digestive organ cancers. Here, EZH2 is linked to prostate carcinoma.